3-Hydroxyglutaric Acid

If a baby or child has unexplained movement problems, episodes of brain swelling, or a Reye-like illness, doctors hunt for clues in the urine. One of the clearest clues is 3-HGA (3-hydroxyglutaric acid), a small organic acid that piles up when a specific enzyme in the body's protein-handling machinery is missing or broken.

This test exists almost entirely to diagnose and monitor glutaric aciduria type I (GA1), a rare inherited disorder that can cause severe, permanent brain injury if missed. Knowing your child's level, or your own as an asymptomatic carrier-parent flagged through newborn screening, can change treatment decisions before damage is done.

What 3-Hydroxyglutaric Acid Actually Is

3-HGA is a small acid (a dicarboxylic organic acid) that the body produces when it tries to break down three amino acids: lysine, hydroxylysine, and tryptophan. Normally, an enzyme called glutaryl-CoA dehydrogenase finishes that breakdown process. When this enzyme is missing or weak, an intermediate compound called glutaryl-CoA accumulates, and your body converts some of it into 3-HGA, which then spills into urine and other fluids.

The acid shows up in urine, blood, spinal fluid, and amniotic fluid at low levels in healthy people, and at higher levels in people with the enzyme defect. The brain seems particularly vulnerable to this buildup, which is why elevated 3-HGA is more than a lab curiosity. It marks a process that can injure deep brain structures responsible for movement.

Why It Matters for Glutaric Aciduria Type I

GA1 is the main reason to test for urinary 3-HGA. Without early detection and treatment, most children with GA1 develop bilateral injury to the striatum, the part of the brain that controls movement, leading to severe dystonia that is often irreversible. Crises tend to strike between roughly 3 and 36 months of age, frequently triggered by a fever, infection, or surgery.

The diagnostic challenge is that some people with GA1, known as low excretors, have normal or only slightly elevated urinary glutaric acid, the more familiar marker. In a study of 25 confirmed GA1 patients, quantitative urinary 3-HGA measured by a stable-isotope dilution assay correctly identified every case, including the low excretors. Spanish cohort data confirm the same pattern: some patients had normal glutaric acid but 3-HGA modestly above controls, which still flagged them as affected.

How Levels Differ Between Healthy People and GA1 Patients

Across published studies, urinary 3-HGA in healthy people sits at very low levels. In GA1 patients classified as high excretors, levels run many times higher than in healthy controls and are usually accompanied by markedly elevated glutaric acid. In low excretors, urinary glutaric acid may sit at or only slightly above the healthy range, but 3-HGA is still modestly elevated above healthy levels, which is what allows quantitative 3-HGA to flag cases that glutaric acid alone misses.

Sources: Barić et al. 1999; Busquets et al. 2000.

What this means for you: a clearly elevated result strongly points toward GA1 and should trigger genetic and enzyme confirmation. A mildly elevated result in the right clinical setting should not be dismissed, because low-excretor GA1 can hide behind borderline numbers.

Brain Injury Risk and Neurological Outcomes

Inside the brain, 3-HGA acts as a neurotoxic metabolite. Brain imaging using 1H-MRS in 13 GA1 patients showed that the high-excreter phenotype was linked to greater cerebral accumulation of glutaric acid and signs of nerve cell compromise. A national follow-up study of 107 GA1 patients found that the biochemical high-excreter phenotype was the major risk factor for cognitive impairment, independent of treatment quality or visible striatal damage on imaging.

A separate analysis of 168 GA1 patients showed that high excretors were also more prone to incidental subdural hematomas (bleeding around the brain), even when newborn screening had caught them early. A study of 21 GA1 patients further found frequent subclinical peripheral nerve involvement, suggesting the metabolic toxicity reaches beyond the brain.

Kidney Function

GA1 also affects kidney health over time. A national study of 94 patients tracked through newborn screening found that while adherence to recommended therapy improved neurological outcomes, kidney dysfunction was unaffected by current treatment protocols. The implication is that even well-managed GA1 patients should be monitored for kidney function over the long term.

Other Conditions That Can Raise 3-HGA

While GA1 is the dominant reason for elevated urinary 3-HGA, the acid can show up modestly in other settings. In a study of 61 autistic children, those with atopic dermatitis had higher urinary 3-HGA than autistic children without dermatitis in initial analysis, though it did not remain an independent predictor after adjusting for other variables. 3-HGA is also one of several organic acids checked as a second-tier test in newborn screening for short-chain acyl-CoA dehydrogenase deficiency, where it helps refine interpretation rather than diagnose the disease on its own.

Persistent isolated elevations of 3-HGA without the full GA1 pattern have also been described in people who turned out not to have the enzyme deficiency on confirmatory testing. This is why specialists treat 3-HGA as one piece of a larger biochemical and genetic picture.

Reconciling the Findings

Two facts can feel contradictory at first: 3-HGA is described as both highly accurate for GA1 and as occasionally elevated in people who do not have GA1. Both are true because 3-HGA is not a simple good number, bad number marker. It is a pathway indicator. In the right clinical context, especially in a baby with neurological symptoms or a positive newborn screen, even modest elevations are meaningful and should be followed up. Outside that context, mild elevations can reflect other metabolic noise and need to be interpreted alongside genetic and enzyme testing before any conclusion is drawn.

Tracking Your Trend

Single urinary organic acid results can be ambiguous. A 10-year external quality assurance program found that when findings were less obvious, the content and clarity of reports from labs varied widely, and repeat testing on a fresh sample was rarely suggested. That gap matters: a fresh urine sample is low risk and often informative, and a trend across multiple measurements is more reliable than any one reading.

For someone with confirmed GA1, periodic urinary 3-HGA monitoring during routine metabolic follow-up provides a check on the underlying disease state and helps inform treatment intensity. For someone with a borderline or isolated elevation, a repeat measurement on a fresh sample, ideally interpreted alongside other organic acids and glutarylcarnitine, is the first step before any leap to a diagnosis.

When Results Can Be Misleading

Urinary organic acid measurements can be distorted by several factors that have nothing to do with GA1. Knowing them helps you avoid the wrong conclusion from a single reading.

• Ambiguous low-level elevations: small elevations of 3-HGA can appear in people who do not have GA1, so isolated mild readings require repeat testing and additional metabolic context before any conclusion.
• Collection variability: urinary organic acid concentrations vary substantially within the same person from sample to sample, so a single result captures only a snapshot.
• Markers can be non-specific: related screening markers like C5-OH acylcarnitine overlap between affected and unaffected individuals, which means any single biochemical clue must be interpreted alongside the full pattern, not in isolation.
• Sample handling: urine organic acid analysis depends on proper collection and rapid processing; degraded samples can produce misleading patterns.

What an Unexpected Result Should Prompt

If urinary 3-HGA comes back elevated, the next step is rarely a single answer. It is a structured workup. Quantitative measurement of both 3-HGA and glutaric acid by a sensitive method, blood glutarylcarnitine (C5DC) on dried blood spot, and confirmatory testing with either GCDH enzyme activity in cells or molecular analysis of the GCDH gene together establish or rule out GA1. Atypical or low-excretor patterns should prompt referral to a specialized metabolic center, because national outcome data show that supervision by experienced metabolic teams measurably improves neurological outcomes.

If results are normal but clinical suspicion remains high, repeat testing on a fresh sample and brain imaging can both be informative, since rare GA1 cases with normal biochemistry but characteristic brain findings have been described. A positive maternal newborn screen flagging an infant's abnormal C5DC can also lead to identification of asymptomatic adult GA1 in the mother, opening the door to preventive therapy.

How This Fits With Newborn Screening

Population newborn screening in many regions detects GA1 primarily through elevated C5DC on blood spots, with urinary organic acids (including 3-HGA) serving as second-line confirmatory testing. Some GA1 cases are still missed by this approach, particularly low excretors with near-normal C5DC. In those situations, clinical features and brain imaging may be the first clue, and urinary 3-HGA becomes part of the targeted workup. Machine-learning approaches now aim to reduce false positives from blood screening, which would cut down on unnecessary follow-up urine, genetic, and enzyme tests.